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Objective. In a context of inﬂammatory disease such as juvenile idiopathic arthritis (JIA), we do not know what impact physical
activity may have on a deregulated immune system. The objective is to measure the impact of a single bout of exercise on
plasma inﬂammatory markers such as calprotectin, IL-6, sIL-6R, sgp130, and the hypothalamic-pituitary-adrenal axis in
children with juvenile idiopathic arthritis. Methods. Twelve children with JIA performed a nonexercise control day and a
consecutive day that included a 20min exercise bout at 70% of max-HR at 08:30 am. Venous blood samples were taken at 08:30,
08:50, 09:30, 10:30 am, and 12:00 pm to measure plasma concentrations of calprotectin, IL-6, sIL-6R, sgp130, cortisol, and
ACTH. Pain was evaluated at 08:30, 08:50 am, and 06:00 pm. Results. There was a transient twofold increase in postexercise self-
evaluated pain (p = 0 03) that disappeared in the evening. A single bout of exercise resulted in a 1.7-fold increase in plasma
calprotectin (p < 0 001) but not IL-6 and its soluble receptors. Calprotectin levels returned to baseline within 3 hours after
cessation of exercise. Conclusion. Acute exercise in children with JIA induced slightly musculoskeletal leg pain and transient
increased plasma calprotectin levels but not IL-6 levels. Trial registration in ClinicalTrials.gov, reference number NCT
02502539, registered on 29 May 2015.
1. Introduction
Juvenile idiopathic arthritis (JIA), the most common
inﬂammatory pathology in children, is a chronic disease
characterized by persistent joint inﬂammation due to
immune system disruption [1]. Some of the proteins that per-
petuate inﬂammatory mechanisms in JIA are calgranulins
(myeloid-related protein (MRP)-8 and MRP-14). They are
secreted by activated monocytes and phagocytes and
induce the expression of proinﬂammatory cytokines (IL-
1β, IL-6, or TNF) [2]. In JIA, the MRP8/14 complex, also
called calprotectin, is a reliable marker of subclinical disease
activity [3, 4].
It has emerged that exercise may have direct eﬀects not
only on metabolic and ﬁtness parameters but also on the
pathogenesis of autoimmune diseases as it attenuates chronic
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low-grade systemic inﬂammation [5]. After acute exercise of
varying intensities and lengths, plasma calprotectin levels in
healthy adults increase at a rate of between 3.4-fold (VO2
max test) and 96.3-fold (marathon) [6]. Although IL-6 is
known as a potent proinﬂammatory signal (involved in the
pathology of JIA), the transient rise in circulating IL-6 during
exercise appears to have anti-inﬂammatory eﬀects [7]. In
addition, IL-6 released from contracting muscle acts in a
hormone-like manner to mobilize extracellular substrates
or inhibits low-level TNF-α production. Likewise, physical
activity is known to impact the hypothalamic-pituitary-
adrenal (HPA) axis in healthy children [8-10] and modulate
the anti-inﬂammatory eﬀect of cortisol. However, the dis-
turbed HPA axis in JIA leads to impaired secretion of adre-
nocorticotropic hormone (ACTH) and cortisol [11, 12].
Even though physical activity is increasingly recognized as a
useful intervention in patients with rheumatisms [13], to
our knowledge, there is no data on the eﬀect of acute bouts
of physical activity on IL-6 and its receptors, calprotectin
and HPA axis in children with inﬂammatory disease.
Here, we set out to explore the impact of an acute bout
exercise on pain and on the secretion of molecules involved
in the inﬂammatory process in JIA.
2. Methods
Twelve children aged 8 to 16 years with nonsystemic JIA
according to the criteria of the International League of Asso-
ciations for Rheumatology were enrolled in the study and
were followed at the pediatric unit of Clermont-Ferrand Uni-
versity Hospital in France.
Patients were excluded if they had a physician-diagnosed
infection, had been treated by IL-6 blockade in the last 6
months, and had received oral corticosteroids within the last
3 months. Treatments were continued during the study.
The study was approved by the governing ethics commit-
tee (Comité de Protection des Personnes Sud-Est VI, refer-
ence number: AU1190). All participants and their parents
have given consent.
Experimental design consisted of two consecutive days
(day 1: control, day 2: exercise day).
Pain was self-evaluated by the patient on a visual analog
scale at 08:30, 08:50 am, and 06:00 pm during the 2 days.
The exercise test consisted of a 20min bout, between
08:30 am and 08:50 am, at 70% of the maximal theoretical
heart rate (max-HR) performed on a cycle ergometer
(Ergo-metrics 800S, Ergoline, Bitz, Germany) during day 2.
Theoretical max-HR was deﬁned as 220-age.
Venous blood samples were taken via an indwelling cath-
eter at 08:30, 08:50, 09:30, 10:30 am, and 12:00 pm, into
EDTA K2 Vacutainer® tubes (Becton Dickinson, Franklin
Lakes, NJ, USA) for analysis of ACTH, IL-6, sIL-6R,
sgp130, and calprotectin, into Vacutainer Lithium Heparin
Tubes (Becton Dickinson, Franklin Lakes, NJ, USA) for anal-
ysis of hs-CRP and into Vacutainer SST II Advance Tubes
(Becton Dickinson, Franklin Lakes, NJ, USA) for analysis of
cortisol. Samples collected for calprotectin, IL-6, sIL-6R,
and sgp130 were immediately centrifuged at 3000g for
10min at 4°C and stored at −80°C until analysis, while all
other blood samples were analyzed immediately.
Plasma ACTH levels were measured by chemilumi-
nescent immunometric assay (Immulite 2000, Siemens
Healthcare Diagnostics; analytical sensitivity = 5 pg/mL).
Serum cortisol levels were measured by chemiluminescence
on an ADVIA Centaur XP Analyzer (Siemens Healthcare
Diagnostics; analytical sensitivity = 27.6 nmol/L). Plasma
MRP8/14 levels were measured using commercially avail-
able ELISA kits (Bühlmann Laboratories, Schönenbuch,
Switzerland; analytical sensitivity = 400ng/mL). Plasma
highly sensitive C-reactive protein (hs-CRP) levels were
measured by nephelometry on a Dimension Vista® ana-
lyzer (Siemens Healthcare Diagnostics; analytical sensitivi-
ty = 0.16mg/L). Plasma IL-6 levels were measured using
commercially available ELISA kits (EH2IL65, Thermo
Fisher Scientiﬁc, USA; analytical sensitivity< 1 pg/mL).
Plasma sgp130 levels were measured using commercially
available ELISA kits (EHIL6ST, Thermo Fisher Scientiﬁc,
USA; analytical sensitivity = 4 pg/mL). Plasma sIL6-R levels
were measured using commercially available ELISA kits
(KHR0061, Thermo Fisher Scientiﬁc, USA; analytical sensiti-
vity =<8 pg/mL). All analyses were made on duplicates.
Statistical analyses were performed using Stata software
version 13 (StataCorp, College Station, TX, USA). Tests
were two-sided, with a type I error set at α = 0 05. Contin-
uous data were expressed as mean± standard deviation
(SD) or median (interquartile range) according to statistical
distribution (assumption of normality assessed by using the
Shapiro-Wilk test). To take into account between- and
within-patient variability due to several measures for the
same subject, random eﬀects models for correlated data were
performed rather than the usual statistical tests which would
be inappropriate due to unveriﬁed assumption of indepen-
dence. Time-point evaluations, sessions, and their interac-
tions were considered ﬁxed eﬀects whereas a patient was a
random eﬀect (slope and intercept). The normality of resid-
uals from these models was studied as described above.
When appropriate, the data were log-transformed to achieve
normality of the dependent endpoint.
3. Results
Baseline patient characteristics are reported in Table 1. Mean
age was 12.3± 2.8 years, BMI was 19.7± 2.9 kg/m2, and dis-
ease duration was 29.4± 18.4 months. Mean fasting hs-CRP
was 0.33± 0.4mg/L.
Exercise bout induced a transient but signiﬁcant increase
in pain postexercise that resolved in few hours (Figure 1).
This musculoskeletal pain involved muscles and joints,
mainly in the legs.
Exercise induced a 1.7-fold increase in calprotectin level
immediately after the exercise (p < 0 001) that returned to
normal within three hours after the end of the exercise bout
(Figure 2). However, there was no eﬀect of exercise on IL-6,
sIL-6R, and sgp130 levels (Figure 3).
Area under the curve (AUC) for plasmatic ACTH and
serum cortisol decreased, respectively, from 11.8% (from
3228± 128 to 2848± 124; p = 0 58) to 17.4% (from 43,455
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± 1294 to 35,943± 1217; p = 0 06) between the nonexercise
control day and the exercise day (Figure 4).
4. Discussion
Overall, the exercise session was well tolerated in all children.
There was a slight increase in pain immediately postexercise,
but the eﬀect was transient and disappeared before the eve-
ning. In terms of pain, it is therefore conceivable to advocate
exercise in this child population, as more and more studies
are showing that physical activity improves quality of life
and symptoms in JIA patients [14, 15].
In healthy adults, acute exercise is known to induce a sig-
niﬁcant secretion of calprotectin [6] and IL-6 [7] by muscle
in an exercise intensity-dependent manner. In fact, exercise
promotes muscle recruitment of activated neutrophils, this
phenomenon is followed by a systemic counterregulation
involving IL-10 and IL-1ra [7]. Here, we observed a slight
increase of calprotectin and no eﬀect on IL-6. The absence
of IL-6 increase could be explained by the short duration
and a low intensity of the exercise bout tested. Furthermore,
as exercise does not increase calprotectin levels in neutrophils
[6], the likely source is skeletal muscle, since S100A8 and
S100A9 mRNA rates increase in skeletal muscle during exer-
cise [16]. Therefore, as our child population has a lower mus-
cle mass and incomplete muscular recruitment [17], there is
likely a lower production of calprotectin and IL-6 by the
muscles than in adults. In addition, pubertal status, physical
exercise training, and BMI seem to be factors involved in
the impact of exercise-induced IL-6 release in children
[18, 19]. Nevertheless, in our child population with systemic
low-grade inﬂammation, as in studies in children with
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Figure 1: Pain evaluations by visual analog scale during the
control day (black bar) and exercise day (white bar). Data are
means± 95% CI.
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Figure 2: Plasma levels of calprotectin during the control day
(solid line) and in response to 20min of exercise (Ex) between
08:30 and 08:50 am (dotted line). Data are means± 95% CI.
∗ Signiﬁcantly diﬀerent to baseline at p < 0 05. ∗∗ Signiﬁcantly
diﬀerent to baseline at p < 0 001.
Table 1: Baseline demographics, clinical characteristics, and baseline laboratory ﬁndings.
Age (years) Sex BMI (kg/m2) Z score JIA subtype
Disease duration
(months)
Concomitant
DMARDs
hs-CRP
(mg/L)ǂ
Heart rate during exercise:
min–max (bpm)
11 F 14.8 −1.4 Psoriatic 16.8 MTX 0.24 141–149
10 M 18.1 +0.6 ERA 14.1 Sulfasalazine <0.16 144–150
8 F 21.7 +1.8 pJIA RF− 4.9 MTX 1.4 142–152
9 M 15.5 −0.4 ERA 35.6 MTX <0.16 143–152
14 F 19.7 +0.2 pJIA RF− 9.0 MTX <0.16 140–149
14 M 20.1 +0.3 Psoriatic 40.1 Inﬂiximab + leﬂunomide 0.33 141–149
16 F 21.1 +0.2 ERA 25.8 NSAIDs 0.53 138–147
9 M 21.3 +1.7 oJIA 55.2 NSAIDs <0.16 140–151
15 F 23.1 +0.9 ERA 20.7 NSAIDs <0.16 140–149
13 F 19.4 +0.2 pJIA RF+ 23.0 MTX+ etanercept <0.16 138–150
12 F 16.9 −0.5 Undif 67 None <0.16 139–151
16 F 24.4 +1.0 Undif 20.5 Etanercept 0.22 138–147
JIA: juvenile idiopathic arthritis; oJIA: oligoarticular JIA; pJIA RF−: rheumatoid factor-negative (RF−) polyarticular JIA; pJIA RF+: rheumatoid factor-positive
(RF+) polyarticular JIA; ERA: enthesitis-related arthritis; Psoriatic: psoriatic JIA; Undif: undiﬀerentiated; DMARDs: disease-modifying antirheumatic drugs;
MTX: methotrexate; NSAIDs: nonsteroidal anti-inﬂammatory drugs; hs-CRP: high-sensitivity C-reactive protein; bpm: beats per minute. ǂNormal
value < 3.0 mg/L. Values of <0.16 are below the minimum detectable limit of the kit.
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obesity or type 1 diabetes, single bout exercise is not followed
by increased IL-6 levels [19]. Finally, the fact that our patients
are under medication (methotrexate or TNF-α inhibitor)
may also explain the discrepancy between the results found
here and data in adult or healthy subjects. A calprotectin
outbreak may have been feared in response to exercise in a
context of proinﬂammatory disease, this is not the case in
response to an acute exercise of moderate intensity.
IL-6 is involved not only in the activation of the immune
system but also in regenerative processes and in the regula-
tion of metabolism, the maintenance of bone homeostasis,
and many neural functions [7, 20]. IL-6 is usually concerned
as a proinﬂammatory cytokine. However, in the setting of
muscular release, it is known to induce anti-inﬂammatory
eﬀects with inhibition of TNF-α production and may
thus prevent TNF-α-induced insulin resistance [7]. Taken
together, these observations raise questions over the diﬀerent
role for IL-6 in children compared to adults, making it neces-
sary to address whether acute physical activity is followed by
systemic counterregulation in children with JIA.
IL-6 acts through a heterodimeric signaling complex
consisting of the IL-6 receptor (IL-6R) and the signal-
transducing subunit glycoprotein 130 (gp130). Trans-
signaling of IL-6 through its soluble receptors is involved in
the promotion of chronic inﬂammatory diseases [21, 22].
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Figure 3: Plasma level of IL-6, sgp130, and sIL-6R during the
control day (solid line) and in response to 20min of exercise (Ex)
between 08:30 and 08:50 am (dotted line). Area under the curve
(AUC) for plasma sIL-6R decreased 8.4% between control day
and exercise day (from 63.36 106± 1.06 106 to 58.03 106± 0.97 106;
p = 0 006). AUC for plasma sgp130 increased 2.6% between
control day and exercise day (from 188.96 106± 4.81 106 to 193.91
106± 5.08 106; p = 0 11). Data are means± 95% CI.
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Figure 4: HPA axis secretion in children with JIA. Serum cortisol
level and plasma ACTH level during the control day (solid line)
and in response to 20min of exercise (Ex) between 08:30 and
08:50 am (dotted line). ∗ Signiﬁcantly diﬀerent to baseline at p <
0 05. ∗∗ Signiﬁcantly diﬀerent to baseline at p < 0 001. Data are
means± 95% CI.
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Concerning the soluble receptors of IL-6, our results showed
no eﬀect of exercise on plasma sgp130 and sIL-6R levels.
These results can be explained by the small number of
patients and the fact that within-subject variation was lower
than between-subject variation for IL-6, sIL-6R, and sgp130
in response to exercise, as reported in another study [23].
This ﬁnding can also in part explain why data on the eﬀect
of exercise on the rate of sgp130 is contradictory, with reports
citing either an increase or a decrease or no eﬀect [23-28].
Furthermore, all IL-6 family cytokines use gp130 as a
receptor [29], and this may partly explain the high concen-
trations of this receptor and its homeostasis. Finally, our
levels of sIL-6R and sgp130 are higher than reported in
literature, although sIL-6R levels are high in the serum
and synovial ﬂuid of JIA patients [30]; this discrepancy
could be explained by the fact that we have used plasma
or by the detection kits used.
We did not observe any impact of physical activity on the
HPA axis except for cortisol. The decrease in cortisol level
observed on the second day was probably due to lower stress
at this session, as the children were aware of the study envi-
ronment, contrary to the ﬁrst session.
The relatively small number of patients could be consid-
ered as a limitation. A second limitation is that it focused on
the physiological response to exercise at blood level, which
may not be an accurate reﬂection of the muscular or articular
response in this population. However, muscle biopsies or
articular aspirations in these children would have been
complicated to perform. Nevertheless, further research is
warranted to conﬁrm our results and evaluate other markers
involved in the inﬂammatory response to exercise in children
(healthy or with an inﬂammatory pathology).
5. Conclusion
This study found that in children with JIA, exercise is
followed by a transient mild proinﬂammatory systemic
response and low musculoskeletal leg pain, which resolve
within three hours.
Data Availability
The data used to support the ﬁndings of this study are
available from the corresponding author upon request.
Conflicts of Interest
The authors declare that they have no conﬂicts of interest
Acknowledgments
This work was supported by a grant from the Clermont-
Ferrand University Hospital (AOI 2015). The authors
thank the pediatric nurse Alexandra Usclade; the data
manager Aurélie Chausset and Khaled Messaoudi, Chloé
Plantard, and Clara Martin for their help with handling
the blood sampling.
References
[1] Y.-T. Lin, C.-T. Wang, M. E. Gershwin, and B.-L. Chiang,
“The pathogenesis of oligoarticular/polyarticular vs systemic
juvenile idiopathic arthritis,” Autoimmunity Reviews, vol. 10,
no. 8, pp. 482–489, 2011.
[2] C. Kessel, D. Holzinger, and D. Foell, “Phagocyte-derived
S100 proteins in autoinﬂammation: putative role in patho-
genesis and usefulness as biomarkers,” Clinical Immunology,
vol. 147, no. 3, pp. 229–241, 2013.
[3] J. Gerss, J. Roth, D. Holzinger et al., “Phagocyte-speciﬁc S100
proteins and high-sensitivity C reactive protein as biomarkers
for a risk-adapted treatment to maintain remission in juvenile
idiopathic arthritis: a comparative study,” Annals of the Rheu-
matic Diseases, vol. 71, no. 12, pp. 1991–1997, 2012.
[4] H. Moncrieﬀe, S. Ursu, D. Holzinger et al., “A subgroup
of juvenile idiopathic arthritis patients who respond well
to methotrexate are identiﬁed by the serum biomarker
MRP8/14 protein,” Rheumatology, vol. 52, no. 8, pp. 1467–
1476, 2013.
[5] B. Gualano, A. L. Sá Pinto, B. Perondi et al., “Evidence for pre-
scribing exercise as treatment in pediatric rheumatic diseases,”
Autoimmunity Reviews, vol. 9, no. 8, pp. 569–573, 2010.
[6] M. K. Fagerhol, H. G. Nielsen, A. Vetlesen, K. Sandvik, and
T. Lyberg, “Increase in plasma calprotectin during long-
distance running,” Scandinavian Journal of Clinical and Labo-
ratory Investigation, vol. 65, no. 3, pp. 211–220, 2005.
[7] M. Gleeson, N. C. Bishop, D. J. Stensel, M. R. Lindley, S. S.
Mastana, and M. A. Nimmo, “The anti-inﬂammatory eﬀects
of exercise: mechanisms and implications for the prevention
and treatment of disease,” Nature Reviews Immunology,
vol. 11, no. 9, pp. 607–615, 2011.
[8] E. Richmond and A. D. Rogol, “Endocrine responses to
exercise in the developing child and adolescent,” Frontiers
of Hormone Research, vol. 47, pp. 58–67, 2016.
[9] A. Viru, L. Laaneots, K. Karelson, T. Smirnova, and M. Viru,
“Exercise-induced hormone responses in girls at diﬀerent
stages of sexual maturation,” European Journal of Applied
Physiology, vol. 77, no. 5, pp. 401–408, 1998.
[10] Y. Kilian, F. Engel, P. Wahl, S. Achtzehn, B. Sperlich, and
J. Mester, “Markers of biological stress in response to a single
session of high-intensity interval training and high-volume
training in young athletes,” European Journal of Applied Phys-
iology, vol. 116, no. 11-12, pp. 2177–2186, 2016.
[11] P. Picco, M. Gattorno, M. P. Sormani et al., “Involvement
of the hypothalamic-pituitary-adrenal axis in children with
oligoarticular-onset idiopathic arthritis,” Annals of the New
York Academy of Sciences, vol. 966, no. 1, pp. 369–372,
2002.
[12] Y. Bilginer, R. Topaloglu, A. Alikasifoglu et al., “Low cortisol
levels in active juvenile idiopathic arthritis,” Clinical Rheuma-
tology, vol. 29, no. 3, pp. 309–314, 2010.
[13] G. Kuntze, C. Nesbitt, J. L. Whittaker et al., “Exercise therapy
in juvenile idiopathic arthritis: a systematic review and meta-
analysis,” Archives of Physical Medicine and Rehabilitation,
vol. 99, no. 1, pp. 178–193.e1, 2018.
[14] T. Takken, M. Van Brussel, R. H. H. Engelbert, J. Van Der Net,
W. Kuis, and P. J. M. Helders, “Exercise therapy in juvenile
idiopathic arthritis: a Cochrane review,” European Journal
of Physical and Rehabilitation Medicine, vol. 44, no. 3,
pp. 287–297, 2008.
5Mediators of Inﬂammation
[15] L. Brosseau, D. B. Maltais, G. P. Kenny et al., “What we
can learn from existing evidence about physical activity for
juvenile idiopathic arthritis?,” Rheumatology, vol. 55, no. 3,
pp. 387-388, 2016.
[16] O. H. Mortensen, K. Andersen, C. Fischer et al., “Calprotectin
is released from human skeletal muscle tissue during exercise,”
The Journal of Physiology, vol. 586, no. 14, pp. 3551–3562,
2008.
[17] S. Ratel, P. Duché, and C. A. Williams, “Muscle fatigue during
high-intensity exercise in children,” Sports Medicine, vol. 36,
no. 12, pp. 1031–1065, 2006.
[18] B. W. Timmons, “Paediatric exercise immunology: health and
clinical applications,” Exercise Immunology Review, vol. 11,
pp. 108–144, 2005.
[19] G. Paltoglou, M. Schoina, G. Valsamakis et al., “Interrelations
among the adipocytokines leptin and adiponectin, oxidative
stress and aseptic inﬂammation markers in pre- and early-
pubertal normal-weight and obese boys,” Endocrine, vol. 55,
no. 3, pp. 925–933, 2017.
[20] M. A. Febbraio and B. K. Pedersen, “Muscle-derived interleu-
kin-6: mechanisms for activation and possible biological
roles,” The FASEB Journal, vol. 16, no. 11, pp. 1335–1347,
2002.
[21] H. Chen, X. Zhang, N. Liao, and F. Wen, “Increased levels of
IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of
patients with diabetic retinopathy,” Molecular Vision, vol. 22,
pp. 1005–1014, 2016.
[22] J. Wolf, S. Rose-John, and C. Garbers, “Interleukin-6 and its
receptors: a highly regulated and dynamic system,” Cytokine,
vol. 70, no. 1, pp. 11–20, 2014.
[23] I. Walshe, P. Robson-Ansley, A. St Clair Gibson,
C. Lawrence, K. G. Thompson, and L. Ansley, “The reliability
of the IL-6, sIL-6R and sgp130 response to a preloaded time
trial,” European Journal of Applied Physiology, vol. 110, no. 3,
pp. 619–625, 2010.
[24] S. R. Gray, M. Robinson, and M. A. Nimmo, “Response of
plasma IL-6 and its soluble receptors during submaximal
exercise to fatigue in sedentary middle-aged men,” Cell
Stress & Chaperones, vol. 13, no. 2, pp. 247–251, 2008.
[25] M. Leggate, M. A. Nowell, S. A. Jones, and M. A. Nimmo, “The
response of interleukin-6 and soluble interleukin-6 receptor
isoforms following intermittent high intensity and continuous
moderate intensity cycling,” Cell Stress & Chaperones, vol. 15,
no. 6, pp. 827–833, 2010.
[26] S. Patterson, S. Reid, S. Gray, andM. Nimmo, “The response of
plasma interleukin-6 and its soluble receptors to exercise in the
cold in humans,” Journal of Sports Sciences, vol. 26, no. 9,
pp. 927–933, 2008.
[27] C. Keller, A. Steensberg, A. K. Hansen, C. P. Fischer,
P. Plomgaard, and B. K. Pedersen, “Eﬀect of exercise, train-
ing, and glycogen availability on IL-6 receptor expression in
human skeletal muscle,” Journal of Applied Physiology,
vol. 99, no. 6, pp. 2075–2079, 2005.
[28] M. Robinson, S. R. Gray, M. S. Watson et al., “Plasma IL-6,
its soluble receptors and F2-isoprostanes at rest and during
exercise in chronic fatigue syndrome,” Scandinavian Journal
of Medicine & Science in Sports, vol. 20, no. 2, pp. 282–290,
2010.
[29] L. Cron, T. Allen, and M. A. Febbraio, “The role of gp130
receptor cytokines in the regulation of metabolic homeostasis,”
Journal of Experimental Biology, vol. 219, no. 2, pp. 259–265,
2016.
[30] N. J. Peake, K. Khawaja, A. Myers et al., “Interleukin-6 signal-
ling in juvenile idiopathic arthritis is limited by proteolytically
cleaved soluble interleukin-6 receptor,” Rheumatology, vol. 45,
no. 12, pp. 1485–1489, 2006.
6 Mediators of Inﬂammation
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
